Related references
Note: Only part of the references are listed.Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors
Harun Ilhan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Wenjia Zhu et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms
Kok Haw Jonathan Lim et al.
NEUROENDOCRINOLOGY (2020)
Role of the bone microenvironment in bone metastasis of malignant tumors-therapeutic implications
Xiaoting Ma et al.
CELLULAR ONCOLOGY (2020)
The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration
Marco E. Bianchi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors
Maximilien Minon et al.
ENDOCRINE (2020)
Orbital metastases from neuroendocrine neoplasms: clinical implications and outcomes
Lukasz Kamieniarz et al.
ENDOCRINE (2020)
Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors (NETs): A sequential case series.
Hagen F. Kennecke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices
Natasha Rekhtman et al.
MODERN PATHOLOGY (2019)
Multimodality Imaging of the Pancreatic Neuroendocrine Tumors
Amandeep Singh et al.
SEMINARS IN ULTRASOUND CT AND MRI (2019)
Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study
Lijie Song et al.
CANCER MEDICINE (2019)
Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study
Deise Uema et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors
Yi Li et al.
NUCLEAR MEDICINE COMMUNICATIONS (2019)
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Alberto Carmona-Bayonas et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management
Barbara Altieri et al.
CANCERS (2019)
214 Population-Based Outcomes of Paragangliomas in British Columbia
Michael Waine et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study
Zhibo Zheng et al.
CANCER MEDICINE (2019)
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours
Francesca M. Rizzo et al.
BRITISH JOURNAL OF CANCER (2019)
Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms
Jeffery Chakedis et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2019)
325. Feasibility of a combination of 90Y/177Lu-Radiopeptide Therapy (Peptide Receptor Radionuclide Therapy – PRRT) and External Beam Radiation Therapy (EBRT) in neuroendocrine tumors (NETs)
S. Vitali et al.
Physica Medica-European Journal of Medical Physics (2019)
The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice
Krystallenia Alexandraki et al.
ENDOCRINE (2019)
Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
Linn Hagmarker et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?
Ali Pirasteh et al.
CLINICAL AND TRANSLATIONAL IMAGING (2019)
Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms
Michelle Guan et al.
ADVANCES IN RADIATION ONCOLOGY (2019)
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Hendrik Bergsma et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
Narjess Ayati et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study
Francesca Marciello et al.
NEUROENDOCRINOLOGY (2018)
Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance
Michael Scharf et al.
NEUROENDOCRINOLOGY (2018)
The Clinicopathological Aspects of Primary Presacral Neuroendocrine Neoplasms: One Center Experience
Guoqing Yang et al.
PANCREAS (2018)
Results of treatment for thymic neuroendocrine tumours: multicentre clinicopathological study
Naoko Ose et al.
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY (2018)
Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response
Emily Vaughan et al.
BRITISH JOURNAL OF RADIOLOGY (2018)
External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review
D. L. Chan et al.
CLINICAL ONCOLOGY (2018)
Radiological features and metastatic patterns of thymic neuroendocrine tumours
T. Araki et al.
CLINICAL RADIOLOGY (2018)
Clinical and Prognostic Value of PET/CT Imaging with Combination of Ga-68-DOTATATE and F-18-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
Panpan Zhang et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2018)
Novel Functional Imaging of Neuroendocrine Tumors
Anders Sundin
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
Ulrike Garske-Roman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Vertebral metastases from neuroendocrine tumours: How to avoid false positives on 68Ga-DOTA-TOC PET using CT pattern analysis?
Mathieu Gauthe et al.
EUROPEAN RADIOLOGY (2018)
Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases
Luciana Audi Castroneves et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT
Ferdinand Seith et al.
RADIOLOGIA MEDICA (2018)
Capecitabine and temozolomide (CAPTEM) for intermediate to high grade metastatic neuroendocrine tumours (NET): A single centre experience.
Arvind Sahu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours
Faidon-Marios Laskaratos et al.
NEUROENDOCRINOLOGY (2018)
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors
Marta Peri et al.
JOURNAL OF THORACIC DISEASE (2018)
Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs)
Olatunji B. Alese et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience
K. N. Lokesh et al.
SOUTH ASIAN JOURNAL OF CANCER (2018)
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
Alexandre Chicheportiche et al.
EJNMMI PHYSICS (2018)
Comparison of the Impact of Ga-68-DOTATATE and F-18-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
Emmanouil Panagiotidis et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors
Lina Carlbom et al.
UPSALA JOURNAL OF MEDICAL SCIENCES (2017)
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial
Andrew L. Himelstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT Case report and review of the literature
Alberto Bongiovanni et al.
MEDICINE (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
Anders Sundin et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress
Paola Jimenez et al.
CURRENT ONCOLOGY REPORTS (2017)
Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro
Mauro Cives et al.
ONCOTARGET (2017)
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients
Julien Hadoux et al.
HORMONES & CANCER (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment
Hossein Jadvar
AMERICAN JOURNAL OF ROENTGENOLOGY (2017)
Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group
Rachel P. Riechelmann et al.
ECANCERMEDICALSCIENCE (2017)
Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
S. Van Binnebeek et al.
EUROPEAN RADIOLOGY (2016)
Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours
Ashley Kieran Clift et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2016)
The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom
Evangelia Skoura et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition
Mauro Cives et al.
NEUROENDOCRINOLOGY (2016)
Hepatic Resection for Metastatic Neuroendocrine Cancer in Patients with Bone Metastases
Kristopher P. Croome et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients
Bruno Conte et al.
CLINICAL COLORECTAL CANCER (2016)
The epidemiology of metastases in neuroendocrine tumors
Matias Riihimaeki et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors
Noura Benslama et al.
INVESTIGATIONAL NEW DRUGS (2016)
Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma
Jian Yu Xu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Peptide receptor radionuclide therapy for metastatic paragangliomas
David J. Pinato et al.
MEDICAL ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical value of 68Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET)
D. R. Albanus et al.
EUROPEAN JOURNAL OF RADIOLOGY (2015)
Bone Metastases in Well-to-Moderately Differentiated Neuroendocrine Tumors A Single Institutional Review From the Ohio State University Medical Center
Juraj Kavecansky et al.
PANCREAS (2015)
897 Prognostic Heterogeneity Among Patients With Bone Metastases From Well-Differentiated Digestive Neuroendocrine Tumors
Maxime Palazzo et al.
GASTROENTEROLOGY (2015)
Bone metastases and skeletal-related events from neuroendocrine tumors
Katherine Van Loon et al.
ENDOCRINE CONNECTIONS (2015)
18F-FDG PET/CT rarely provides additional information other than primary tumor detection in patients with pulmonary carcinoid tumors
Ebru Tatci et al.
ANNALS OF THORACIC MEDICINE (2014)
Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?
Duygu Has Simsek et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sequelae and survivorship in patients treated with 131I-MIBG therapy
W. C. C. Sze et al.
BRITISH JOURNAL OF CANCER (2013)
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT
A. Kroiss et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases
P. Bhosale et al.
EUROPEAN RADIOLOGY (2013)
Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: A study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center
Elena B. Hawryluk et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Neuroendocrine ACTH-Producing Tumor of the Thymus-Experience with 12 Patients over 25 Years
Nicola M. Neary et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E plus O) or placebo (P plus O) among patients with advanced neuroendocrine tumors (NET).
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Incidence and natural history of bone metastases in neuroendocrine tumors
Jennifer Keiser et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions
Esther I. van Vliet et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Neuroendocrine Tumors Clinical Practice Guidelines in Oncology
Matthew H. Kulke et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
Marianne Pavel et al.
NEUROENDOCRINOLOGY (2012)
Skeletal metastasis of carcinoid tumors: Two case reports and review of the literature
Takeshi Hori et al.
ONCOLOGY LETTERS (2012)
Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
Alexander R. Haug et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
Daniel Hubble et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours
Valentina Ambrosini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Unfavorable Prognosis of Small Cell Neuroendocrine Carcinoma of the Uterine Cervix A Retrospective Matched Case-Control Study
Shin Wha Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors
Beata Kos-Kudla et al.
NEUROENDOCRINOLOGY (2010)
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours
Alexander Haug et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
Daniel Putzer et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases
Sue Chua et al.
SEMINARS IN NUCLEAR MEDICINE (2009)
Validation of Symptom Clusters in Patients with Metastatic Bone Pain
Edward Chow et al.
Current Oncology (2008)
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Ulrich-Frank Pape et al.
ENDOCRINE-RELATED CANCER (2008)
99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours:: results of 3 years' experience
A. Hubalewska-Dydejczyk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours
M Rodrigues et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors - Variables affecting response rates and survival
S Gupta et al.
CANCER (2005)
Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor
M Katai et al.
ENDOCRINE JOURNAL (2005)
Metastatic carcinoid tumors: A clinical review
JM Zuetenhorst et al.
ONCOLOGIST (2005)
Octreoscan in patients with bronchial carcinoid tumours
D Granberg et al.
CLINICAL ENDOCRINOLOGY (2003)
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1
F Gibril et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
SPECT/CT hybrid imaging with In-111-pentetreotide in assessment of neuroendocrine tumours
Y Krausz et al.
CLINICAL ENDOCRINOLOGY (2003)
Natural history of neuroendocrine enteropancreatic tumors
M Mignon
DIGESTION (2000)
Share Paper
